Digitalis Ventures

Galatea Bio is a biotechnology company based in the United States, founded by Carlos Bustamante, Nicholas Katsanis, and Alexander Ioannidis. The company focuses on improving diagnostic testing and accelerating drug discovery specifically for diverse and underserved populations that have historically been underrepresented in genetics research. Galatea Bio operates a biobank that serves as a biosample and bioinformatics platform, utilizing advanced algorithms and innovative analyses to facilitate genomic discoveries. Through its world-class clinical network, the company aims to identify patients at risk for severe multi-inflammatory syndromes or infections, ultimately working to develop new tests, treatments, and cures that enhance healthcare outcomes for all.

Judo Bio is a biotechnology company developing precision therapeutics that target specific cell populations to address genetic diseases. Its innovative receptor targeting approach aims to benefit patients with both common and rare diseases.

GRO Biosciences employs computational protein design and synthetic biology to enhance protein therapeutics. It has developed multiple genomically recoded bacterial strains capable of incorporating non-standard amino acids into proteins, resulting in improved potency, stability, and targeted delivery. The company focuses on developing advanced treatments for diabetes, growth disorders, and autoimmunity.

Founded in 2017 by Dr. Matthew Hill, Elegen is a biotechnology company specializing in microfluidic technology for the development of advanced DNA synthesizers. Its mission is to accelerate biomedical progress through innovative synthetic biology solutions.

EpiBiologics is a biotechnology company focused on developing antibody-based targeted therapies aimed at membrane and extracellular proteins that contribute to various diseases. Utilizing its proprietary EpiTAC platform, EpiBiologics creates therapeutics designed to degrade these disease-driving proteins, addressing the underlying biology of a wide range of disorders. The company's innovative approach enables researchers to manipulate cellular proteostasis, offering potential advancements in the treatment of challenging health conditions.

Good Therapeutics, Inc. is a biotechnology company based in Seattle, Washington, founded in 2016. The company specializes in developing innovative biotherapeutics and self-regulating drugs that provide therapeutic activity in a context-dependent manner. Their core technology involves designing allosterically-regulated proteins that can detect specific biomarkers and respond accordingly, activating therapeutic functions only when and where needed. This approach aims to enhance drug safety and efficacy by reducing systemic toxicity while maintaining therapeutic effectiveness. Currently, Good Therapeutics is primarily focused on applications within immuno-oncology, aiming to create safer and more effective treatment options that optimize patient outcomes.

Founded in 2017 by Dr. Matthew Hill, Elegen is a biotechnology company specializing in microfluidic technology for the development of advanced DNA synthesizers. Its mission is to accelerate biomedical progress through innovative synthetic biology solutions.

Galatea Bio is a biotechnology company based in the United States, founded by Carlos Bustamante, Nicholas Katsanis, and Alexander Ioannidis. The company focuses on improving diagnostic testing and accelerating drug discovery specifically for diverse and underserved populations that have historically been underrepresented in genetics research. Galatea Bio operates a biobank that serves as a biosample and bioinformatics platform, utilizing advanced algorithms and innovative analyses to facilitate genomic discoveries. Through its world-class clinical network, the company aims to identify patients at risk for severe multi-inflammatory syndromes or infections, ultimately working to develop new tests, treatments, and cures that enhance healthcare outcomes for all.

GRO Biosciences employs computational protein design and synthetic biology to enhance protein therapeutics. It has developed multiple genomically recoded bacterial strains capable of incorporating non-standard amino acids into proteins, resulting in improved potency, stability, and targeted delivery. The company focuses on developing advanced treatments for diabetes, growth disorders, and autoimmunity.

AnimalBiome specializes in personalized pet nutrition, focusing on improving gut health for dogs and cats through microbiome science. The company offers microbiome tests to analyze pets' gut bacteria and provides tailored restorative supplements sourced from healthy animals to balance the microbiome.

Rejuvenate Bio Inc is a biotechnology company based in Brookline, Massachusetts, that focuses on developing gene therapies to enhance health and extend the lifespans of dogs and other domesticated animals. Founded in 2017, the company utilizes innovative approaches derived from research at the Wyss Institute at Harvard Medical School to create anti-aging therapies and address age-related diseases. By introducing new DNA instructions into the bodies of pets, Rejuvenate Bio aims to offer solutions for chronic conditions and improve overall well-being. The company's gene therapy pipeline is designed to target specific diseases and leverage clinically validated gene targets to ensure effective and lasting results.

SeQure DX is a biotechnology company specializing in genomics diagnostics for CRISPR-based gene editing therapies. It develops technologies that identify potential off-target sites prior to therapy initiation, ensuring comprehensive confirmation of actual edits. This enables safer and more effective gene editing therapeutics development, benefiting both researchers and patients.

Base5 Genomics, Inc. is a biotechnology firm focused on developing sequencing solutions aimed at enhancing personalized care. Founded in 2018 and headquartered in Palo Alto, California, the company specializes in revealing the full genomic diversity in humans and other organisms. Its technologies are particularly significant in the fields of cancer biology, DNA damage and repair, genome organization, and gene regulation. By providing insights into genetic makeup, Base5 Genomics enables the medical community to advance personalized medicine, facilitating tailored treatments that meet the specific needs of patients.

Good Therapeutics, Inc. is a biotechnology company based in Seattle, Washington, founded in 2016. The company specializes in developing innovative biotherapeutics and self-regulating drugs that provide therapeutic activity in a context-dependent manner. Their core technology involves designing allosterically-regulated proteins that can detect specific biomarkers and respond accordingly, activating therapeutic functions only when and where needed. This approach aims to enhance drug safety and efficacy by reducing systemic toxicity while maintaining therapeutic effectiveness. Currently, Good Therapeutics is primarily focused on applications within immuno-oncology, aiming to create safer and more effective treatment options that optimize patient outcomes.

GRO Biosciences employs computational protein design and synthetic biology to enhance protein therapeutics. It has developed multiple genomically recoded bacterial strains capable of incorporating non-standard amino acids into proteins, resulting in improved potency, stability, and targeted delivery. The company focuses on developing advanced treatments for diabetes, growth disorders, and autoimmunity.

Good Therapeutics, Inc. is a biotechnology company based in Seattle, Washington, founded in 2016. The company specializes in developing innovative biotherapeutics and self-regulating drugs that provide therapeutic activity in a context-dependent manner. Their core technology involves designing allosterically-regulated proteins that can detect specific biomarkers and respond accordingly, activating therapeutic functions only when and where needed. This approach aims to enhance drug safety and efficacy by reducing systemic toxicity while maintaining therapeutic effectiveness. Currently, Good Therapeutics is primarily focused on applications within immuno-oncology, aiming to create safer and more effective treatment options that optimize patient outcomes.

Founded in 2012, Girihlet is a biotechnology company based in Oakland, California. It specializes in accurate profiling of T cell receptor repertoires using innovative sequencing technologies, aiming to advance understanding and management of immune system-related disorders.

Rejuvenate Bio Inc is a biotechnology company based in Brookline, Massachusetts, that focuses on developing gene therapies to enhance health and extend the lifespans of dogs and other domesticated animals. Founded in 2017, the company utilizes innovative approaches derived from research at the Wyss Institute at Harvard Medical School to create anti-aging therapies and address age-related diseases. By introducing new DNA instructions into the bodies of pets, Rejuvenate Bio aims to offer solutions for chronic conditions and improve overall well-being. The company's gene therapy pipeline is designed to target specific diseases and leverage clinically validated gene targets to ensure effective and lasting results.

GRO Biosciences employs computational protein design and synthetic biology to enhance protein therapeutics. It has developed multiple genomically recoded bacterial strains capable of incorporating non-standard amino acids into proteins, resulting in improved potency, stability, and targeted delivery. The company focuses on developing advanced treatments for diabetes, growth disorders, and autoimmunity.